Academic anti CD19 CAR-T cell therapy for relapsed/refractory B-cell lymphomas in real-world clinical practice: a prospective cohort study - Quiz - MDSpire

Academic anti CD19 CAR-T cell therapy for relapsed/refractory B-cell lymphomas in real-world clinical practice: a prospective cohort study

  • By

  • Natalya E. Konoplya

  • Tatiana M. Doroshenko

  • Katsiaryna Yu. Zharkova

  • Tatyana V. Savich

  • Ihar M. Seviaryn

  • Nadezhda M. Bobrova

  • Alexey A. Beleevsky

  • Eldar Kh. Sarydze

  • Sergey L. Polyakov

  • July 17, 2026

Share

Original Source(s)

Academic anti CD19 CAR-T cell therapy for relapsed/refractory B-cell lymphomas in real-world clinical practice: a prospective cohort study

  • by Natalya E. Konoplya, Tatiana M. Doroshenko, Katsiaryna Yu. Zharkova, Tatyana V. Savich, Ihar M. Seviaryn, Nadezhda M. Bobrova, Alexey A. Beleevsky, Eldar Kh. Sarydze, Sergey L. Polyakov

  • July 17, 2026

Related Content

Spinal metastases in geriatric patients: a retrospective single-center comparison of mortality and surgical outcomes following neurosurgical treatment

Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis

CRISPR/Cas9 in cancer therapy: clinical translation, mechanistic strategies, and therapeutic directions